## CENTER FOR DRUG EVALUATION AND RESEARCH

**APPLICATION NUMBER:** 

210136Orig1s000

# **REMS**

## **Risk Evaluation and Mitigation Strategy (REMS) Document**

## **BRIXADI (buprenorphine) extended-release REMS**

## I. Administrative Information

Risk: Serious harm or death that could result from intravenous self-administration Application Number: NDA 210136 Application Holder: Braeburn Inc. Initial REMS Approval: 05/2023

## II. REMS Goal

The goal of the BRIXADI REMS is to mitigate the risk of serious harm or death that could result from intravenous self-administration by:

• Ensuring healthcare settings and pharmacies are certified and only dispense BRIXADI directly to a healthcare provider for administration by a healthcare provider.

## **III. REMS Requirements**

Braeburn Inc. must ensure that healthcare settings, pharmacies, and wholesalers-distributors comply with the following requirements:

## 1. Healthcare settings and pharmacies that dispense BRIXADI must:

To become certified to dispense	1.	Designate an authorized representative to carry out the certification process and oversee implementation and compliance with the REMS on behalf of the healthcare setting or pharmacy.
	2.	Have the authorized representative enroll in the REMS by completing the Healthcare Setting and Pharmacy Enrollment Form and submitting it to the REMS.
	3.	Train all relevant staff involved in dispensing that the drug must be dispensed directly to a healthcare provider for administration by a healthcare provider, and the drug must not be dispensed to the patient.
	4.	Establish processes and procedures to verify BRIXADI is dispensed directly to a healthcare provider and the drug is not dispensed to the patient.
	5.	Establish processes and procedures to notify the healthcare provider not to dispense the drug directly to patients.
Before dispensing	6.	Verify that BRIXADI is dispensed directly to a healthcare provider and the drug is not dispensed to the patient.
	7.	Notify the healthcare provider not to dispense the drug directly to patients.

To maintain certification to dispense	8. Have a new authorized representative enroll in the REMS by completing and submitting the Healthcare Setting and Pharmacy Enrollment Form, if the authorized representative changes.
At all times	<ol> <li>9. Not distribute, transfer, loan or sell BRIXADI.</li> <li>10. Maintain records of all processes and procedures including compliance with those processes and procedures.</li> </ol>
	11. Comply with audits by Braeburn Inc. or a third party acting on behalf of Braeburn Inc. to ensure that all processes and procedures are in place and are being followed.

## 2. Wholesalers-Distributors that distribute BRIXADI must:

To be able to distribute	<ol> <li>Establish processes and procedures to ensure that the drug is distributed only to certified healthcare settings and pharmacies.</li> </ol>	d
	2. Train all relevant staff involved in distributing BRIXADI on the process an procedures to verify the healthcare settings and pharmacies are certified	
At all times	3. Distribute only to certified healthcare settings and pharmacies.	
	4. Maintain and submit records of all shipments of BRIXADI to Braeburn Inc	c.
	<ol> <li>Comply with audits carried out by Braeburn Inc. or a third party acting of behalf of Braeburn Inc. to ensure that all processes and procedures are in place and are being followed.</li> </ol>	

## To inform healthcare providers about the REMS and the risks and safe use of BRIXADI, Braeburn Inc. must disseminate REMS communication materials according to the table below:

Target Audience	Communication Materials & Dissemination Plans		
All healthcare providers who prescribe buprenorphine for	REMS Letter: Healthcare Provider REMS Letter with attachment: Fact Sheet: How to Obtain BRIXADI.		
the treatment of opioid use disorder; all pharmacies	<ol> <li>Mail within 60 calendar days of the date of the approval of the REMS and again 6 months later, or</li> </ol>		
authorized by DEA to handle schedule III controlled	<ol><li>eMail within 60 calendar days of the date of the approval of the REMS and again 6 months later.</li></ol>		
substances; all Opioid Treatment Programs certified	3. Make available via a link from the BRIXADI REMS Website.		
under 42 CFR 8	<ol> <li>Disseminate within 60 calendar days of the date of the approval of the REMS through professional societies and request the content be provided to their members.</li> </ol>		
	a. The professional societies are identified in Appendix A.		
	5. Disseminate at Professional Meetings where Braeburn Inc. has a presence for 1 year from the date of the approval of the REMS.		
All new healthcare providers who prescribe buprenorphine	REMS Letter: Healthcare Provider REMS Letter with attachment: Fact Sheet: How to Obtain BRIXADI		

Target Audience	Communication Materials & Dissemination Plans
for the treatment of opioid	6. Mail annually from the date of the approval of the REMS, or
use disorder since the last dissemination; all pharmacies authorized by DEA to handle schedule III controlled substances since the last dissemination; all Opioid Treatment Programs certified under 42 CFR 8 since the last dissemination	7. eMail annually from the date of the approval of the REMS.

## To support REMS operations, Braeburn Inc. must:

- Establish and maintain a REMS website, www.BRIXADIREMS.com. The REMS website must include the capability to complete healthcare setting and pharmacy certification online, the option to print the Prescribing Information, Medication Guide, and REMS materials. All product websites for consumers and healthcare providers must include prominent REMS-specific links to the REMS website. The REMS website must not link back to the promotional product website.
- 2. Make the REMS website fully operational and all REMS materials available through website and call center by the date BRIXADI is first commercially distributed.
- 3. Establish and maintain a REMS call center for REMS participants at 1-866-492-9624.
- 4. Establish and maintain a validated, secure database of all REMS participants who are enrolled and/or certified in the BRIXADI REMS.
- 5. Ensure healthcare settings and pharmacies are able to enroll by fax, mail, email, and online.
- 6. Provide Healthcare Provider REMS Letter, Fact Sheet: How to Obtain BRIXADI, Healthcare Setting and Pharmacy Enrollment Form and the Prescribing Information to REMS participants who (1) attempt to dispense BRIXADI and are not yet certified or (2) inquire about how to become certified.
- 7. Notify healthcare settings and pharmacies, confirming certification, within 7 calendar days after they become certified in the REMS.
- 8. Provide wholesalers-distributors access to the database of certified healthcare settings and pharmacies.

## To ensure REMS participants' compliance with the REMS, Braeburn Inc. must:

- 9. Verify annually that the authorized representative's name and contact information correspond to those of the current designated authorized representative for the certified healthcare setting or pharmacy. If different, the healthcare setting and pharmacy must be required to re-certify with a new authorized representative.
- 10. Maintain adequate records to demonstrate that REMS requirements have been met, including, but not limited to records of: BRIXADI distribution and dispensing; certification of pharmacies and healthcare settings; and audits of REMS participants.
- 11. Establish and maintain a plan for addressing non-compliance with REMS requirements.
- 12. Monitor healthcare settings, pharmacies, and wholesalers-distributors on an ongoing basis to ensure the requirements of the REMS are being met. Take corrective action if non-compliance is identified, including de-certification.

- 13. Audit a representative sample of healthcare settings no later than 90 calendar days after the healthcare setting is certified and receives its first shipment of BRIXADI, and audit a representative sample annually thereafter, to ensure that all REMS processes and procedures are in place, functioning, and support the REMS requirements.
- 14. Audit all pharmacies no later than 90 calendar days after the pharmacy is certified and receives its first shipment of BRIXADI, and audit a representative sample annually thereafter, to ensure that all REMS processes and procedures are in place, functioning, and support the REMS requirements.
- 15. Audit all wholesalers-distributors no later than 90 calendar days after they become authorized, and audit all wholesalers-distributors annually thereafter, to ensure that all REMS processes and procedures are in place, functioning, and support the REMS requirements.
- 16. Take reasonable steps to improve operations of and compliance with the requirements in the BRIXADI REMS based on monitoring and evaluation of the BRIXADI REMS.

## IV. REMS Assessment Timetable

Braeburn Inc. must submit REMS Assessments at 6 months, 12 months, and annually thereafter from the date of the initial approval of the REMS (05/23/2023). To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 calendar days before the submission date for that assessment. Braeburn Inc. must submit each assessment so that it will be received by the FDA on or before the due date.

## V. **REMS Materials**

The following materials are part of the BRIXADI REMS and are appended:

## **Enrollment Forms:**

Healthcare Setting and Pharmacy:

1. Healthcare Setting and Pharmacy Enrollment Form

## **Communication Materials**

- 2. Healthcare Provider REMS Letter
- 3. Fact Sheet: How to Obtain BRIXADI

## **Other Materials**

4. REMS Website

## VI. Statutory Elements

This REMS is required under section 505-1 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355-1) and consists of the following elements:

- 1. Elements to Assure Safe Use (ETASU):
  - Pharmacies and health care settings that dispense BRIXADI are specially certified under 505-1(f)(3)(B)

- 2. Implementation System
- 3. Timetable for Submission of Assessments

## **Appendix A: List of Professional Societies**

- AATOD American Association of the Treatment of Opioid Dependence
- ASAM American Society of Addiction Medicine
- AAAP American Association of Addiction Psychiatry
- ABAM American Board of Addiction Medicine
- FSMB Federation of State Medical Boards
- ACEP American College of Emergency Physicians
- NCPA National Community of Pharmacists Association
- ASHP American Society of Health-System Pharmacists
- AOAAM American Osteopathic Academy of Addiction Medicine
- AANP American Association of Nurse Practitioners
- AAPA American Association of Physician Assistants
- AphA American Pharmacists Association



(buprenorphine) extended-release injection for subcutaneous use (

## HEALTHCARE SETTING AND PHARMACY ENROLLMENT FORM

BRIXADI is only available through the BRIXADI Risk Evaluation and Mitigation Strategy (REMS).

#### Instructions

If a healthcare setting or a pharmacy intends to store a supply of and order BRIXADI directly from an authorized distributor, certification in the BRIXADI REMS is required. To become certified, healthcare settings and pharmacies must:

- 1. Designate an Authorized Representative who can ensure the Authorized Representative responsibilities listed in the "Authorized Representative Information and Responsibilities" section of the enrollment form are met and that each dispensing location meets the REMS requirements.
- 2. Agree to:
  - Train all relevant staff at each dispensing location involved in dispensing the drug directly to a healthcare provider, to ensure that the drug is not dispensed directly to a patient.
  - Establish process and procedures to verify that BRIXADI is dispensed directly to a healthcare provider. **Do not dispense BRIXADI directly to a patient.**
  - Establish process and procedures to notify the healthcare provider not to dispense BRIXADI directly to patients.
- Complete and sign this BRIXADI REMS Healthcare Setting and Pharmacy Enrollment Form and submit it to the BRIXADI REMS.

Once certification of the healthcare setting/pharmacy is complete, a notification will be provided to the Authorized Representative.

Only one (1) form is needed per healthcare setting. A pharmacy is covered under their healthcare setting's enrollment in the BRIXADI REMS.

## Certification in the BRIXADI REMS is not required if a healthcare setting intends to only obtain BRIXADI for administration by a practitioner at a specific named patient's scheduled appointment from a REMS-certified pharmacy.

The BRIXADI REMS Healthcare Setting and Pharmacy Enrollment Form contains two sections:

- "Authorized Representative Information and Responsibilities" section page 2
- "Healthcare Setting and Pharmacy Information" section page 3

For the initial enrollment, both sections noted above must be submitted. For **each** additional healthcare setting/ pharmacy where BRIXADI will be delivered, dispensed, and administered within your healthcare system for which the same Authorized Representative is responsible, the Authorized Representative will need to complete the "Healthcare Setting and Pharmacy Information" section on page 3.

If a designated Authorized Representative changes, the new Authorized Representative must complete and sign a new **BRIXADI REMS Healthcare Setting and Pharmacy Enrollment Form**, including a "Healthcare Setting Information" section for each healthcare setting with which he/she is now affiliated.

To enroll, complete all required fields on the form and one "Healthcare Setting / Pharmacy Information" section for each dispensing site and submit via:

- Online: <u>www.BRIXADIREMS.com</u>
- FAX: 1-833-274-8597
- Email: <u>BRIXADIREMS@braeburnrx.com</u>
- Mail: BRIXADI REMS Program, 6923 Lee Vista Blvd, Ste 300, Orlando, FL 32822

For questions regarding the BRIXADI REMS or how to enroll, visit <u>www.BRIXADIREMS.com</u> or contact the BRIXADI REMS at 1-866-492-9624.

## HEALTHCARE SETTING AND PHARMACY ENROLLMENT FORM (cont'd)

Authorized Repres	sentative Information an	d Responsibilities		
AUTHORIZED REPR	ESENTATIVE INFORMAT	TION (*REQUIRED FIELD	DS)	
Role*				
□ Nurse	□ Nurse Practitioner	🗌 Pharmacist	🗌 Physician	🗌 Physician Assistant
Practice Manager	Other:			
Contact details*				
First name:	Last	name:		Middle initial:
Position/Title:				
Telephone number:	Alter	nate telephone number:_	Offic	e fax:
Email:		Preferred method of	communication:	] Fax 🗌 Email 🗌 Phone

I am the Authorized Representative designated to carry out the certification process and oversee implementation and compliance with the REMS on behalf of my healthcare setting or pharmacy. By signing this form, I agree to:

- Certify in the BRIXADI REMS by completing the Healthcare Setting and Pharmacy Enrollment Form and submitting it to the REMS.
- Train all relevant staff involved in dispensing that the drug must be dispensed directly to a healthcare provider for administration by a healthcare provider, and that BRIXADI must not be dispensed directly to a patient.
- Establish processes and procedures to verify BRIXADI is dispensed directly to a healthcare provider, and BRIXADI is not dispensed to a patient.
- Establish processes and procedures to notify the healthcare provider not to dispense directly to patients. Notifications may be accomplished through a variety of mechanisms based on the healthcare setting. Phone calls, an auxiliary label printed automatically and affixed to the dispensed prescription, or reminders in the electronic medical record are potential mechanisms to communicate the alert.
- Not distribute, transfer, loan, or sell BRIXADI.
- Maintain records of all processes and procedures including compliance with those processes and procedures.
- Comply with audits by Braeburn or a third party acting on behalf of Braeburn to ensure that all processes and procedures are in place and being followed for the BRIXADI REMS.

By checking this box, you understand that your healthcare setting/pharmacy may be selected for audit within 90 days.

Healthcare Setting or Pharmacy Authorized Representative Signature\*:

Date\* (MM/DD/YYYY): \_\_\_\_ /\_\_\_ /

By signing I acknowledge that I understand that there is a risk of serious harm or death that could result from intravenous self-administration of BRIXADI, and to not dispense BRIXADI directly to a patient. I understand that this enrollment applies to my healthcare setting(s) or pharmacy(ies) for which I am the designated Authorized Representative.

## BRIXADI REMS

(buprenorphine) extended-release injection for subcutaneous use @

## HEALTHCARE SETTING AND PHARMACY ENROLLMENT FORM (cont'd)

Healthcare Setting and Pharmacy Informat	ion			
Healthcare Setting/Pharmacy Name:				
Street Address:	City:	State:	ZI	P:
Facility Identifiers (provide at least 1) NPI:	NCPDP:		_ DEA:	
Authorized Representative Name:				
Primary Point of Contact IF NOT the Authorized	Representative:			
Point of Contact Name:				
Street Address:	City:	State:	ZIP:	
Telephone Number: Alter	nate Telephone Number	:	Office F	ax:
Email:	Preferred Method of C	Communication:	∃Fax ⊡Er	mail 🗌 Phone
Setting Type				
Specialty  Other:				
☐ Healthcare Setting				
🗆 Closed Healthcare System 🛛 Criminal Ju	stice Facility 🛛 Crimir	nal Justice Facility	Pharmacy	
Department of Defense (DoD) Facility	]Federally Qualified Hea	Ith Center (FQHC)	🗆 FQHC F	harmacy
🗆 Group Practice 🛛 Hospital 🗌 Hospital F	Pharmacy 🗌 Independe	ent Practice 🛛 In	stitution	
□ Institution Pharmacy □ Integrated Deliver	y Network (IDN) 🛛 IDN	N Pharmacy 🛛 Op	pioid Treatme	ent Program (OTP
🗌 Outpatient Clinic 🛛 Veterans Administrat	tion (VA) Facility 🛛 VA	Pharmacy		
Other:				

I am the designated Authorized Representative for this healthcare setting or pharmacy.

Healthcare Setting or Pharmacy Authorized Representative Signature:

Date (MM/DD/YYYY): \_\_\_ /\_\_\_ /\_\_\_\_

# **b** braeburn

BRIXADI (buprenorphine) extended-release injection for subcutaneous use CIII

## FDA-REQUIRED REMS SAFETY INFORMATION

## WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; BRIXADI RISK EVALUATION AND MITIGATION STRATEGY

- Serious harm or death could result if administered intravenously. BRIXADI forms a liquid crystalline gel upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously.
- Because of the risk of serious harm or death that could result from intravenous self-administration, BRIXADI is only available through a restricted program called the BRIXADI REMS. Healthcare settings and pharmacies that order and dispense BRIXADI must be certified in this program and comply with the REMS requirements.

[Date]

Dear Healthcare Provider:

The purpose of this letter is to inform you about the **BRIXADI** <u>**R**</u>isk <u>**E**</u>valuation and <u>**M**</u>itigation <u>**S**</u>trategy (**REMS**). The FDA determined that a **REMS** is necessary to ensure that the benefits of BRIXADI outweigh the risk of serious harm or death that could result from intravenous self-administration of BRIXADI.

Per the BRIXADI REMS, BRIXADI is only available through a restricted distribution program.

## **BRIXADI REMS Requirements:**

• Any pharmacy or healthcare setting (including a prescriber office) that intends to store a supply of and order BRIXADI directly from an authorized distributor **must be certified** in the BRIXADI REMS prior to purchasing / dispensing BRIXADI.

**NOTE**: Certification in the BRIXADI REMS is **not required** if a healthcare setting intends to only obtain BRIXADI from a REMS-certified pharmacy for administration by a practitioner at a **specific named patient's scheduled appointment**. The REMS-certified pharmacy will coordinate delivery to the administering practitioner with the patient's appointment.

- Healthcare providers are **not required** to certify in the REMS to prescribe BRIXADI.
- BRIXADI must never be dispensed directly to a patient.

The enclosed *BRIXADI REMS Fact Sheet: How to Obtain BRIXADI*, provides information about **how your healthcare setting or pharmacy can obtain BRIXADI**.

Please visit <u>www.BRIXADIREMS.com</u> or contact the BRIXADI REMS at 1-866-492-9624 for BRIXADI REMS materials and for information about **how your healthcare setting or pharmacy can certify** in the BRIXADI REMS. For medical-related questions, call Braeburn's Information line 1-833-274-9234.

## Indication

BRIXADI is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.

BRIXADI should be used as part of a complete treatment plan to include counseling and psychosocial support.

## **BRIXADI Storage**

Store BRIXADI at room temperature at 20°C to 25°C (68°F to 77°F); with excursions permitted at 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. BRIXADI is a Schedule III drug product. Handle with adequate security and accountability. After administration, syringes should be properly disposed, per facility procedure for a Schedule III drug product, and per applicable federal, state, and local regulations.

Page 2 of 3

## **Reporting Adverse Events**

Healthcare providers are encouraged to report adverse events to the FDA. Healthcare providers should report all cases of intravenous administration and suspected adverse events associated with BRIXADI to the FDA at 1-800-FDA-1088 or online at <a href="http://www.fda.gov/medwatch/report.htm">www.fda.gov/medwatch/report.htm</a> or to Braeburn at 1-833-274-9234 or send information to <a href="http://drugsafety@braeburnrx.com">drugsafety@braeburnrx.com</a>.

Sincerely,

<NAME>

<TITLE> Braeburn

Enclosed:

## BRIXADI REMS Fact Sheet: How to Obtain BRIXADI



## BRIXADI<sup>™</sup> REMS FACT SHEET How to Obtain BRIXADI

## What is the BRIXADI REMS (Risk Evaluation and Mitigation Strategy)?

A REMS is a strategy to manage known or potential risks associated with a drug and is required by the Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks. **BRIXADI is intended for subcutaneous injection only by a healthcare provider** and is only available through a restricted distribution program called the BRIXADI REMS. **BRIXADI must never be dispensed directly to the patient** and **must only be administered by a healthcare professional** in a healthcare setting. The goal of the REMS is to mitigate **the risk of serious harm or death that could result from intravenous self-administration**.

#### **BRIXADI REMS Requirements**

## PRESCRIBER

- 1. Prescribers are **NOT required to be certified** in the BRIXADI REMS to prescribe BRIXADI.
- Prescribers can obtain BRIXADI for a specific named patient's scheduled appointment by writing a prescription and sending it to a REMScertified pharmacy. The REMS-certified pharmacy coordinates delivery to the prescriber or the practitioner administering BRIXADI with the patient's appointment date.
- Prescribers that intend to keep a supply of BRIXADI in stock at their healthcare setting and obtain BRIXADI from a distributor, **must certify** their healthcare setting or practice in the BRIXADI REMS. See below.

## **HEALTHCARE SETTINGS/PHARMACIES**

Any healthcare setting\* (including a prescriber office) or pharmacy that intends to keep a supply of BRIXADI in stock and order BRIXADI directly from an authorized distributor **must be certified** in the BRIXADI REMS prior to purchasing/dispensing BRIXADI.

# How does a healthcare setting\* or pharmacy become certified?

To become certified in the BRIXADI REMS, healthcare settings and pharmacies must:

- 1. Designate an Authorized Representative that agrees to:
  - Train all relevant staff at each dispensing location involved in the dispensing of BRIXADI directly to a healthcare provider, to ensure that the drug is not dispensed directly to a patient.
  - Establish processes and procedures to verify that BRIXADI is dispensed directly to a healthcare provider. BRIXADI must never be dispensed directly to a patient.
  - Establish processes and procedures to notify the healthcare provider not to dispense BRIXADI directly to patients.
- Complete the REMS enrollment process by filling out and signing the Healthcare Setting and Pharmacy Enrollment Form, which may be obtained at www.BRIXADIREMS.com

\*Examples of healthcare settings include: group practice, independent practice, institution, Department of Defense (DoD) facility, outpatient clinic, hospital, Veterans Administration (VA) facility, opioid treatment program (OTP), closed healthcare system, and other healthcare settings.

BRIXADI must never be dispensed directly to a patient.

# Does a prescriber that wants to have BRIXADI administered to a named patient at their scheduled appointment need to certify? How can healthcare providers obtain BRIXADI for their patients?

Prescribers do not need to certify in the REMS. In advance of the patient's appointment, send a prescription for the named patient to a certified pharmacy. REMS-certified pharmacies can be found on the REMS website (www.BRIXADIREMS.com) or by calling 1-866-492-9624. The pharmacy will coordinate delivery with the patient's scheduled appointment and deliver to the prescriber or the administering practitioner designated by the prescriber. **BRIXADI is never dispensed directly to the patient and must only be administered by a healthcare professional in a healthcare setting**.

## Does a prescriber that wants to keep a bulk supply of BRIXADI in stock at their office need to certify? How does a prescriber obtain BRIXADI?

The prescriber's office/healthcare setting must certify in the REMS and obtain BRIXADI through an authorized distributor.

## How should BRIXADI be stored?

Once BRIXADI is delivered for a named patient or is obtained for a healthcare setting's bulk supply:

- Store BRIXADI at room temperature at 20°C to 25°C (68°F to 77°F); with excursions permitted at 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
- BRIXADI is a Schedule III drug product. Handle with adequate security and accountability. After administration, syringes should be properly disposed per facility procedure for a Schedule III drug product and per applicable federal, state, and local regulations.

## Where can I find more information about the BRIXADI REMS?

Visit www.BRIXADIREMS.com to access the following materials:

- BRIXADI REMS Healthcare Setting and Pharmacy Enrollment Form
- BRIXADI REMS Dear Healthcare Provider Letter
- Prescribing Information
- Medication Guide
- REMS-Certified Pharmacy Locator
- List of Authorized Distributors

Contact the BRIXADI REMS at 1-866-492-9624 for BRIXADI REMS materials and for additional information about the BRIXADI REMS.

Visit the REMS@FDA website at <u>https://www.accessdata.fda.gov/scripts/cder/rems/\_index.cfm</u>.

Call Braeburn's information line at 1-833-274-9234.





## Welcome to the BRIXADI REMS (Risk Evaluation and Mitigation Strategy)

## What is the BRIXADI REMS (<u>Risk Evaluation and</u> <u>Mitigation Strategy</u>)?

A REMS is a strategy to manage known or potential risks associated with a drug, and is required by the Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks. **BRIXADI is intended for subcutaneous injection only by a healthcare provider** and is only available through a restricted distribution program called the BRIXADI REMS. BRIXADI must never be dispensed directly to the patient and must only be administered by a healthcare professional in a healthcare setting. The goal of the REMS is to mitigate the risk of serious harm or death that could result from intravenous self-administration.

#### **BRIXADI REMS Requirements**

#### PRESCRIBERS

Brixaci' buprenorphine) extended-relea: njection for subcutaneous use @

1. Prescribers are NOT required to be certified in the BRIXADI REMS to prescribe BRIXADI.

 Prescribers can obtain BRIXADI for a specific named patient's scheduled appointment by writing a prescription and sending it to a REMS-certified pharmacy. The REMS-certified pharmacy coordinates delivery to the prescriber or the practitioner administering BRIXADI with the patient's appointment date.

 Prescribers that intend to keep a supply of BRIXADI in stock at their healthcare setting and obtain BRIXADI from a distributor, must certify their healthcare setting or practice in the BRIXADI REMS. See below.

#### **HEALTHCARE SETTINGS\*/PHARMACIES**

Any healthcare setting<sup>+</sup> (including a prescriber office) or pharmacy that intends to keep a supply of BRIXADI in stock and order BRIXADI directly from an authorized distributor **must be certified** in the BRIXADI REMS prior to purchasing/dispensing BRIXADI.

\* Examples of healthcare settings include: group practice, independent practice, institution, Department of Defense (DoD) facility, outpatient clinic, hospital, Veterans Administration (VA) facility, opioid treatment program (OTP), closed healthcare system, and other healthcare settings.

## How does a healthcare setting or pharmacy become certified in the BRIXADI REMS?

To become certified in the BRIXADI REMS, healthcare settings and pharmacies must:

#### 1. Designate an Authorized Representative that agrees to:

- Train all relevant staff at each dispensing location involved in the dispensing of BRIXADI
  directly to a healthcare provider, to ensure that the drug is not dispensed directly to a
  patient.
- Establish processes and procedures to verify that BRIXADI is dispensed directly to a healthcare provider. BRIXADI must never be dispensed directly to a patient.
- Establish processes and procedures to notify the healthcare provider not to dispense BRIXADI directly to patients.

2. Complete the REMS enrollment process by filling out and signing the Healthcare Setting and Pharmacy Enrollment Form

Does a prescriber that wants to have BRIXADI administered to a named patient at their scheduled appointment need to certify? How can healthcare providers obtain BRIXADI for their patients?

Prescribers do not need to certify in the REMS. In advance of the patient's appointment, send a prescription for the named patient to a certified pharmacy. REMS-certified pharmacies can be found here or by calling 1.866-492-9624. The pharmacy will coordinate delivery with the patient's scheduled appointment and deliver to the prescriber or the administering practitioner designated by the prescriber. BRIXADI is never dispensed directly to the patient and must only be administered by a healthcare professional in a healthcare setting.

#### Does a prescriber that wants to keep a bulk supply of BRIXADI in stock at their office need to certify? How does a prescriber obtain BRIXADI?

#### Resources for Healthcare Providers

- BRIXADI REMS Healthcare Setting and
   Pharmacy Enrollment Form
- BRIXADI REMS Fact Sheet
   Dear Healthcare Provider Letter

BRIXADI must never be dispensed directly to a patient.

The prescriber's office/healthcare setting must certify in the REMS and obtain BRIXADI through an authorized distributor.

#### How should BRIXADI be stored?

Once BRIKADI is delivered for a named patient or is obtained for a healthcare setting's bulk supply:

- Store BRIXADI at room temperature at 20°C to 25°C (68°F to 77°F); with excursions permitted at 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
- BRIXADI is a Schedule III drug product. Handle with adequate security and accountability. After administration, syringes should be properly disposed per facility procedure for a Schedule III drug product and per applicable federal, state, and local regulations.

## Where can healthcare settings and pharmacies find more information about the BRIXADI REMS?

- · Review the following materials:
  - BRIXADI REMS Healthcare Setting and Pharmacy Enrollment Form
  - BRIXADI REMS Fact Sheet: How to Obtain BRIXADI
  - BRIXADI REMS Dear Healthcare Provider Letter
  - Prescribing Information
  - <u>Medication Guide</u>(educational tool designed specifically for patients)
- Contact the BRIXADI REMS at 1-866-492-9624 for REMS materials and for additional information about the BRIXADI REMS.
- Visit the REMS@FDA website at: <u>https://www.accessdata.fda.gov/scripts/cder/rems</u> /index.cfm.
- Call Braeburn's Information line (1-833-274-9234).

Access the current list of certified pharmacies where BRIXADI can be obtained by calling the BRIXADI REMS at 1-866-492-9624.

#### Indication

BRIXADI is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.

BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support.

#### **Reporting Adverse Events**


Healthcare providers are encouraged to report adverse events to the FDA. Healthcare providers should report all cases of intravenous administration and suspected adverse events associated with BRIXADI to the FDA at <u>1-800-FDA-1088</u> or online at <u>www.fda.gov/medwatch/report.htm</u> or to Braeburn at <u>1-833-274-9234</u> or send information to <u>drugsafety@braeburnrx.com</u>.


#### Contact Us

Privacy Policy Terms of Use Medication Guide Prescribing Information

BRIKADI is a registered trademark of Braeburn, Inc. This site is intended for US residents only. 2023 Braeburn, Inc. All rights reserved.









## Brixadi REMS Fact Sheet





## **Privacy Policy**

#### Right Click To Download PDF



🗙 🗣 Page 1 / 7 🛛 🗕 🕂 Zoom 110%

Right Click To Download PDF

#### Contact Us

Privacy Policy Terms of Use Medication Guide Prescribing Information

BRIXADI is a registered trademark of Braeburn, Inc. This site is intended for US residents only. 2023 Braeburn, Inc. All rights reserved.

#### Resources for Healthcare Providers

- BRIXADI REMS Healthcare
   Setting and Pharmacy
   Enrollment Form
- BRIXADI REMS Fact Sheet
   Dear Healthcare Provider
   Letter



BRIXADI must never be dispensed directly to a patient.

## **b** braeburn

(burrenorphine) exterded-release injection for subsutaneous use @	Medication Guide   Prescriting Information
BRIXADI REMS Online Enrollmen	t Form
Please enter your information to receive an email notification from BRIXADI REMS with ins Pharmacy Enrollment Form. Full Name Email	tructions to complete the BRIXADI REMS Healthcare Setting and
SUBMIT	
Contact Us Privacy Policy Terms of Use Medication Guide Prescribing Information	
BRIXADI is a registered trademark of Braeburn, Inc. This site is intended for US residents only. 2023 Braeburn, Inc. All rights reserved.	t braeburn

Thank you for your submission. In moments you will be receiving an email notification from BRIXADI REMS with instructions to complete the BRIXADI REMS Healthcare Setting and Pharmacy Enrollment Form. If you do not receive this email, please call 1-866-492-9624.

#### Resources for Healthcare Providers

- BRIXADI REMS Healthcare
   Setting and Pharmacy
- Enrollment Form
   BRIXADI REMS Fact Sheet
- Dear Healthcare Provider
   Letter



BRIXADI must never be dispensed directly to a patient.

Contact Us Privacy Policy

Terms of Use Medication Guide Prescribing Information

BRIXADI is a registered trademark of Braeburn, Inc. This site is intended for US residents only. 2023 Braeburn, Inc. All rights reserved. t braeburn

## **Email Notification:**

6	braeburn
Braeburn has r	requested form from Braeburn. requested you to review and complete the Healthcare Setting and Pharmacy rm
	g Dropbox Forms to give you the best mobile signing Dropbox Forms for free.
▲ Warning: To pre email.	event others from accessing your account, do not forward this

## Get Started Page:

# **b**raeburn

## BRIXADI REMS Healthcare Setting and Pharmacy Enrollment Form

Click 'Get Started' below to begin.

Authorized Representative Information and Responsibilities

Healthcare Setting and Pharmacy Information Form

Get started

## Authorized Representative Flat Form Details:

# **b** braeburn



# Authorized Representative Information and Responsibilities

BRIXADI is only available through the BRIXADI Risk Evaluation and Mitigation Strategy (REMS).

If a healthcare setting or a pharmacy intends to store a supply of and order BRIXADI directly from an authorized distributor, certification in the BRIXADI REMS is required. To become certified, healthcare settings and pharmacies must:

 Designate an Authorized Representative who can ensure the Authorized Representative responsibilities listed in the "Authorized Representative Information and Responsibilities" section of the enrollment form are met and that each dispensing location meets the REMS requirements.

#### 2. Agree to:

- Train all relevant staff at each dispensing location involved in dispensing the drug directly to a healthcare provider, to ensure that the drug is not dispensed directly to a patient.
- Establish process and procedures to verify that BRIXADI is dispensed directly to a healthcare provider. <u>Do not dispense</u> <u>BRIXADI directly to a patient.</u>
- Establish process and procedures to notify the healthcare provider not to dispense BRIXADI directly to patients.

 Complete and sign this BRIXADI REMS Healthcare Setting and Pharmacy Enrollment Form and submit it to the BRIXADI REMS.

Once certification of the healthcare setting/pharmacy is complete, a notification will be provided to the Authorized Representative.

Only one (1) form is needed per healthcare setting. A pharmacy is covered under their healthcare setting's enrollment in the BRIXADI REMS.

Certification in the BRIXADI REMS is not required if a healthcare setting intends to only obtain BRIXADI for administration by a practitioner at a specific named patient's scheduled appointment from a REMS-certified pharmacy.

The BRIXADI REMS Healthcare Setting and Pharmacy Enrollment Form contains two sections:

- "Authorized Representative Information and Responsibilities" section
- "Healthcare Setting and Pharmacy Information" section

For the initial enrollment, both sections noted above must be submitted. For **each** additional healthcare setting/ pharmacy where BRIXADI will be delivered, dispensed, and administered within your healthcare system for which the same Authorized Representative is responsible, the Authorized Representative will need to complete the "Healthcare Setting and Pharmacy Information" section.

If a designated Authorized Representative changes, the new Authorized Representative must complete and sign a new **BRIXADI REMS Healthcare Setting and Pharmacy Enrollment Form**, including a "Healthcare Setting Information" section for each healthcare setting with which he/she is now affiliated.

This is the online enrollment form. Please complete all required fields in the pages to follow.

For questions regarding the BRIXADI REMS or how to enroll, visit www.BRIXADIREMS.com or contact the BRIXADI REMS at 1-866-492-9624.

## I acknowledge that I have read the instructions (uncheck to review again)

## Request Type \*

- New REMS Request
- Update an Existing REMS

## Role \*

Select an item...

×

#### First Name \*



## Middle Initial

## Last Name \*

l,	þ	
		l.

## Position/Title \*

¦1
----

#### Telephone Number\*

l: 💬

## Alternative Telephone Number

#### Office Fax Number



#### Preferred Method of Communication \*

Select an item...

I am the Authorized Representative designated to carry out the certification process and oversee implementation and compliance with the REMS on behalf of my healthcare setting or pharmacy. By signing this form, I agree to:

- Certify in the BRIXADI REMS by completing the Healthcare Setting and Pharmacy Enrollment Form and submitting it to the REMS.
- Train all relevant staff involved in dispensing that the drug must be dispensed directly to a healthcare provider for administration by a healthcare provider, and that BRIXADI must not be dispensed directly to a patient.
- Establish processes and procedures to verify BRIXADI is dispensed directly to a healthcare provider, and BRIXADI is not dispensed to a patient.
- Establish processes and procedures to notify the healthcare provider not to dispense directly to patients. Notifications may be accomplished through a variety of mechanisms based on the healthcare setting. Phone calls, an auxiliary label printed automatically and affixed to the dispensed prescription, or reminders in the electronic medical record are potential mechanisms to communicate the alert.
- Not to distribute, transfer, loan, or sell BRIXADI.
- Maintain records of all processes and procedures including compliance with those processes and procedures.


 Comply with audits by Braeburn or a third party acting on behalf of Braeburn to ensure that all processes and procedures are in place and being followed for the BRIXADI REMS.

By signing I acknowledge that I understand that there is a risk of serious harm or death that could result from intravenous selfadministration of BRIXADI, and to not dispense BRIXADI directly to a patient. I understand that this enrollment applies to my healthcare setting(s) or pharmacy(ies) for which I am the designated Authorized Representative.

\* By checking this box, you understand that your healthcare setting/pharmacy may be selected for audit within 90 days.



#### Signature Date: 03/21/2023



## Authorized Representative Dynamic Form Details:

## Request Type Update:

New REMS Request Opdate an Existing REMS	
Existing REMS ID to Replace * 🚱	

## Role Types:

#### Role \*

Physician	~
Select an item	
Pharmacist	
Physician Assistant	
Practice Manager	
Nurse	
Nurse Practitioner	
Physician	
Other	

## Role Type "Other" Selection:

#### Role \*

Other ~

## If Other, Please Specify: \*



## First Name \*

Ī

## Preferred Communication Method Options:

### Preferred Method of Communication \*

~

Email

Select an item...

Telephone Number

Alternate Phone Number

Office Fax Number

Email

#### Program Requirements Agreement selection:

I am the Authorized Representative designated to carry out the certification process and oversee implementation and compliance with the REMS on behalf of my healthcare setting or pharmacy. By signing this form, I agree to:

- Certify in the BRIXADI REMS by completing the Healthcare Setting and Pharmacy Enrollment Form and submitting it to the REMS.
- Train all relevant staff involved in dispensing that the drug must be dispensed directly to a healthcare provider for administration by a healthcare provider, and that BRIXADI must not be dispensed directly to a patient.
- Establish processes and procedures to verify BRIXADI is dispensed directly to a healthcare provider, and BRIXADI is not dispensed to a patient.
- Establish processes and procedures to notify the healthcare
  provider not to dispense directly to patients. Notifications may be
  accomplished through a variety of mechanisms based on the
  healthcare setting. Phone calls, an auxiliary label printed
  automatically and affixed to the dispensed prescription, or
  reminders in the electronic medical record are potential
  mechanisms to communicate the alert.
- Not to distribute, transfer, loan, or sell BRIXADI.
- Maintain records of all processes and procedures including compliance with those processes and procedures.
- Comply with audits by Braeburn or a third party acting on behalf of Braeburn to ensure that all processes and procedures are in place and being followed for the BRIXADI REMS.

By signing I acknowledge that I understand that there is a risk of serious harm or death that could result from intravenous selfadministration of BRIXADI, and to not dispense BRIXADI directly to a patient. I understand that this enrollment applies to my healthcare setting(s) or pharmacy(ies) for which I am the designated Authorized Representative.

\* By checking this box, you understand that your healthcare setting/pharmacy may be selected for audit within 90 days.

You must review the terms and conditions before you can submit the REMS request.

Healthcare Setting Flat Form:

← Docu	ment 2 of 2	
Health	care Settii	ng and
Pharm	acy Inform	nation Form
The second se	vledge that I have k to review again)	
Request Ty	pe *	
	IS Request n Existing REMS	
	orized Representative this signature to your	
X CLICK	TO SIGN	
This field has a		

## Healthcare Setting Name\*

Street Address \*

## City \*

State \*

Select an item...

~

## Zipcode \*

Facility Identifiers (Please Provide at least one of the following): \*

NPI

NCPDP

DEA

#### Authorized Representative Name

Jane G Smith

### Point of Contact Name

#### Street Address

## City

## State

Select an item...

Y

## Zipcode

## **Telephone Number**

Alternative Telephone Number

#### **Office Fax Number**

#### Email

#### Reference ID: 5178299

## **Preferred Method of Communication**

Select an item...

Setting Type: \*

_						
PI	ha	r	m	3	C1	1
				d	5	Y

Healthcare Setting


~

\* I am the designated Authorized Representative for this healthcare setting or pharmacy.



### Signature Date: 03/21/2023

I agree to be legally bound by the document, and agree to the Dropbox Sign Terms and Privacy Policy. Click on "I agree" to sign this document.



## Healthcare Setting Dynamic Form Details:

## Facility Identifiers

NPI is required
1234567

## Preferred Method of Communication

## Preferred Method of Communication

Select an item	~
Select an item	
Telephone Number	
Alternate Phone Number	
Office Fax Number	
Email	

## Setting Type Pharmacy Selection:

Pharmacy	Healthcare Setting	
ype of Pharmacy*		
Select an item		
Select an item		

## Setting Type Pharmacy Other Selection and Field:

Pharmacy	Healthcare Setting
Type of Pharmacy*	
Other	
and the second	are not allowed. Any reference to reta REMS request to be rejected.
and the second	REMS request to be rejected.

## Setting Type Healthcare Setting Selected:

Pharmacy	Healthcare Setting
pe of Healthcare Sett	ing *
Select an item	
Select an item	
Closed Healthcare Syste	m
Criminal Justice Facility	
Criminal Justice Facility F	Pharmacy
Department of Defense (	(DoD) Facility
Federally Qualified Healt	th Center (FQHC)
FQHC Pharmacy	
Group Practice	
Hospital	
Hospital Pharmacy	
Independent Practice	
Institution	
Institution Pharmacy	
Integrated Delivery Netw	vork (IDN)
IDN Pharmacy	
Opioid Treatment Progra	im (OTP)
Outpatient Clinic	
Veterans Administration	(VA) Facility
VA Pharmacy	
Other	

Setting Type Healthcare Other Selection and Field:

ype of Healthcare Setting	
Other	~

## Preview Form:

BRIXADI REMS	b braeburn	(buprenorphine) extended-rele injection for subcutaneous use (
HEALTHCARE SETTING AND PHARM. BRIXADI is only available through the BRIXADI Risk		
Instructions		
If a healthcare setting or a pharmacy intends to store certification in the BRIXADI REMS is required. To be		
<ol> <li>Designate an Authorized Representative who in the "Authorized Representative Information that each dispensing location meets the REM</li> </ol>	and Responsibilities" section of the	
<ol> <li>Agree to:         <ul> <li>Train all relevant staff at each dispensing loc provider, to ensure that the drug is not disp</li> <li>Establish process and procedures to verify</li> <li>Do not dispense BRIXADI directly to a paie</li> <li>Establish process and procedures to notify to patients.</li> </ul> </li> </ol>	ensed directly to a patient. that BRIXADI is dispensed directly t atient.	o a healthcare provider.
<ol> <li>Complete and sign this BRIXADI REMS Heat to the BRIXADI REMS.</li> </ol>	lthcare Setting and Pharmacy Enr	ollment Form and submit it
Once certification of the healthcare setting/pharmac Representative.	cy is complete, a notification will be	provided to the Authorized
Only one (1) form is needed per healthcare setting. in the BRIXADI REMS.	A pharmacy is covered under their h	ealthcare setting's enrollmer
Certification in the BRIXADI REMS is obtain BRIXADI for administration by a appointment from		
obtain BRIXADI for administration by a	practitioner at a specific name m a REMS-certified pharmacy.	d patient's scheduled
obtain BRIXADI for administration by a appointment from	practitioner at a specific name m a REMS-certified pharmacy. macy Enrollment Form contains tw	d patient's scheduled
obtain BRIXADI for administration by a appointment from The BRIXADI REMS Healthcare Setting and Phar	practitioner at a specific name m a REMS-certified pharmacy. macy Enrollment Form contains tw desponsibilities" section – page 2	d patient's scheduled
obtain BRIXADI for administration by a appointment from The <i>BRIXADI REMS Healthcare Setting and Phan</i> • "Authorized Representative Information and R	practitioner at a specific name m a REMS-certified pharmacy. macy Enrollment Form contains tw desponsibilities" section – page 2 n" section – page 3 e must be submitted. For each additi sed, and administered within your he o Authorized Representative will need	d patient's scheduled vo sections: onal healthcare setting/ palthcare system for which th
obtain BRIXADI for administration by a appointment from The BRIXADI REMS Healthcare Setting and Phan • "Authorized Representative Information and R • "Healthcare Setting and Pharmacy Information For the initial enrollment, both sections noted above pharmacy where BRIXADI will be delivered, dispensisame Authorized Representative is responsible, the	practitioner at a specific name m a REMS-certified pharmacy. macy Enrollment Form contains tw desponsibilities" section – page 2 n" section – page 3 e must be submitted. For each additi sed, and administered within your he Authorized Representative will need 3. the new Authorized Representative marmacy Enrollment Form, including	d patient's scheduled vo sections: onal healthcare setting/ pathcare system for which th d to complete the "Healthcar must complete and sign
obtain BRIXADI for administration by a appointment from The BRIXADI REMS Healthcare Setting and Phan • "Authorized Representative Information and R • "Healthcare Setting and Pharmacy Information For the initial enrollment, both sections noted above pharmacy where BRIXADI will be delivered, dispens same Authorized Representative is responsible, the Setting and Pharmacy Information" section on page If a designated Authorized Representative changes, a new BRIXADI REMS Healthcare Setting and Pha	practitioner at a specific name m a REMS-certified pharmacy. macy Enrollment Form contains two besponsibilities" section – page 2 n" section – page 3 a must be submitted. For each additt sed, and administered within your he o Authorized Representative will need a 3. the new Authorized Representative marmacy Enrollment Form, including h which he/she is now affiliated.	d patient's scheduled to sections: conal healthcare setting/ ealthcare system for which the d to complete the "Healthcar must complete and sign g a "Healthcare Setting
obtain BRIXADI for administration by a appointment from appointment from "Authorized Representative Information and R  "Authorized Representative Information and R  "Healthcare Setting and Pharmacy Information" For the initial enrollment, both sections noted above pharmacy where BRIXADI will be delivered, dispens same Authorized Representative is responsible, the Setting and Pharmacy Information" section on page If a designated Authorized Representative changes, a new BRIXADI REMS Healthcare Setting and Pharmacy Information" section for each healthcare setting with To enroll, complete all required fields on the form an	practitioner at a specific name m a REMS-certified pharmacy. macy Enrollment Form contains two besponsibilities" section – page 2 n" section – page 3 a must be submitted. For each additt sed, and administered within your he o Authorized Representative will need a 3. the new Authorized Representative marmacy Enrollment Form, including h which he/she is now affiliated.	d patient's scheduled to sections: conal healthcare setting/ ealthcare system for which the d to complete the "Healthcar must complete and sign g a "Healthcare Setting
obtain BRIXADI for administration by a appointment from The BRIXADI REMS Healthcare Setting and Phan • "Authorized Representative Information and R • "Healthcare Setting and Pharmacy Information For the initial enrollment, both sections noted above pharmacy where BRIXADI will be delivered, dispens same Authorized Representative is responsible, the Setting and Pharmacy Information" section on page If a designated Authorized Representative changes, a new BRIXADI REMS Healthcare Setting and Pha Information" section for each healthcare setting with To enroll, complete all required fields on the form ar each dispensing site and submit via:	practitioner at a specific name m a REMS-certified pharmacy. macy Enrollment Form contains two besponsibilities" section – page 2 n" section – page 3 a must be submitted. For each additt sed, and administered within your he o Authorized Representative will need a 3. the new Authorized Representative marmacy Enrollment Form, including h which he/she is now affiliated.	d patient's scheduled to sections: conal healthcare setting/ ealthcare system for which the d to complete the "Healthcar must complete and sign g a "Healthcare Setting
obtain BRIXADI for administration by a appointment from The BRIXADI REMS Healthcare Setting and Phane • "Authorized Representative Information and Re • "Healthcare Setting and Pharmacy Information For the initial enrollment, both sections noted above pharmacy where BRIXADI will be delivered, dispense same Authorized Representative is responsible, the Setting and Pharmacy Information" section on page If a designated Authorized Representative changes, a new BRIXADI REMS Healthcare Setting and Pha Information" section for each healthcare setting with To enroll, complete all required fields on the form are each dispensing site and submit via: • Online: www.BRIXADIREMS.com	practitioner at a specific name m a REMS-certified pharmacy. macy Enrollment Form contains two besponsibilities" section – page 2 n" section – page 3 a must be submitted. For each additt sed, and administered within your he o Authorized Representative will need a 3. the new Authorized Representative marmacy Enrollment Form, including h which he/she is now affiliated.	d patient's scheduled to sections: conal healthcare setting/ ealthcare system for which the d to complete the "Healthcar must complete and sign g a "Healthcare Setting
obtain BRIXADI for administration by a appointment from The BRIXADI REMS Healthcare Setting and Phan • "Authorized Representative Information and R • "Healthcare Setting and Pharmacy Information For the initial enrollment, both sections noted above pharmacy where BRIXADI will be delivered, dispens same Authorized Representative is responsible, the Setting and Pharmacy Information" section on page If a designated Authorized Representative changes, a new BRIXADI REMS Healthcare Setting and Ph Information" section for each healthcare setting wit To enroll, complete all required fields on the form ar each dispensing site and submit via: • Online: www.BRIXADIREMS.com • FAX: 1-833-274-8597	practitioner at a specific name m a REMS-certified pharmacy. macy Enrollment Form contains tw desponsibilities" section – page 2 n" section – page 3 e must be submitted. For each additt sed, and administered within your he o Authorized Representative will need 3. the new Authorized Representative barmacy Enrollment Form, including h which he/she is now affiliated. and one "Healthcare Setting / Pharma	d patient's scheduled to sections: conal healthcare setting/ ealthcare system for which the d to complete the "Healthcar must complete and sign g a "Healthcare Setting
obtain BRIXADI for administration by a appointment from The BRIXADI REMS Healthcare Setting and Phan • "Authorized Representative Information and R • "Healthcare Setting and Pharmacy Information For the initial enrollment, both sections noted above pharmacy where BRIXADI will be delivered, dispens same Authorized Representative is responsible, the Setting and Pharmacy Information" section on page If a designated Authorized Representative changes, a new BRIXADI REMS Healthcare Setting and Ph Information" section for each healthcare setting witt To enroll, complete all required fields on the form ar each dispensing site and submit via: • Online: www.BRIXADIREMS.com • FAX: 1-833-274-8597 • Email: BRIXADIREMS@braebumrx.com	practitioner at a specific name m a REMS-certified pharmacy. macy Enrollment Form contains tw esponsibilities" section – page 2 n" section – page 3 a must be submitted. For <b>each</b> additi sed, and administered within your he o Authorized Representative will need a 3. the new Authorized Representative barmacy Enrollment Form, including h which he/she is now affiliated. nd one "Healthcare Setting / Pharma	d patient's scheduled to sections: onal healthcare setting/ patthcare system for which th d to complete the "Healthcar must complete and sign g a "Healthcare Setting cy Information" section for

Practice Manager Other: Contact details*  First name: Jane Last name: Smith  Position/Title: Physician  Telephone number: 923-885-0931 Alternate telephone number: 923-885	unication: Fax Email Phone ocess and oversee implementation and y signing this form, I agree to:
Role*         Nurse       Nurse Practitioner       Pharmacist         Practice Manager       Other:       Contact details*         First name:       Jane       Last name:       Smith         Position/Title:       Physician       Physician       Practice Methods       Practice Methods         Telephone number:       923-885-0931       Alternate telephone number:       923-885         Email:       jane.smith@testing.org       Preferred method of communication processes         I am the Authorized Representative designated to carry out the certification processes in behalf of my healthcare setting or pharmacy. By       Certify in the BRIXADI REMS by completing the Healthcare Setting and I submitting it to the REMS.         •       Train all relevant staff involved in dispensing that the drug must be dispersion for administration by a healthcare provider, and that BRIXADI must not be         •       Establish processes and procedures to verify BRIXADI is dispensed directed BRIXADI is not dispensed to a patient.         •       Establish processes and procedures to notify the healthcare provider not Notifications may be accomplished through a variety of mechanisms bas calls, an auxiliary label printed automatically and affixed to the dispensed electronic medical record are potential mechanisms to communicate the         •       Not distribute, transfer, loan, or sell BRIXADI.         •       Maintain records of all processes and procedures including compliance w	Middle initial: <u>G</u> 5-9384Office fax: <u>923-885-3728</u> unication: □ Fax □ Email ✔ Phone ocess and oversee implementation and y signing this form, I agree to:
<ul> <li>Nurse</li> <li>Nurse Practitioner</li> <li>Pharmacist</li> <li>Practice Manager</li> <li>Other:</li> <li>Contact details*</li> <li>First name: Jane</li> <li>Last name: Smith</li> <li>Position/Title: Physician</li> <li>Telephone number: 923-885-0931</li> <li>Alternate telephone number: 923-885</li> <li>Email: jane.smith@testing.org</li> <li>Preferred method of communication procompliance with the REMS on behalf of my healthcare setting or pharmacy. By</li> <li>Certify in the BRIXADI REMS by completing the Healthcare Setting and I submitting it to the REMS.</li> <li>Train all relevant staff involved in dispensing that the drug must be dispert for administration by a healthcare provider, and that BRIXADI must not be</li> <li>Establish processes and procedures to verify BRIXADI is dispensed direct BRIXADI is not dispensed to a patient.</li> <li>Establish processes and procedures to notify the healthcare provider not Notifications may be accomplished through a variety of mechanisms bas calls, an auxiliary label printed automatically and affixed to the dispensed electronic medical record are potential mechanisms to communicate the</li> <li>Not distribute, transfer, loan, or sell BRIXADI.</li> <li>Maintain records of all processes and procedures including compliance w</li> </ul>	Middle initial: <u>G</u> 5-9384Office fax: <u>923-885-3728</u> unication: □ Fax □ Email ✔ Phone ocess and oversee implementation and y signing this form, I agree to:
<ul> <li>□ Practice Manager □ Other:</li></ul>	Middle initial: <u>G</u> 5-9384Office fax: <u>923-885-3728</u> unication: □ Fax □ Email ✔ Phone ocess and oversee implementation and y signing this form, I agree to:
Contact details*         First name: Jane       Last name: Smith         Position/Title: Physician         Telephone number: 923-885-0931       Alternate telephone number: 923-885         Email: jane.smith@testing.org       Preferred method of communication procompliance with the REMS on behalf of my healthcare setting or pharmacy. By         I am the Authorized Representative designated to carry out the certification procompliance with the REMS on behalf of my healthcare setting or pharmacy. By         • Certify in the BRIXADI REMS by completing the Healthcare Setting and I submitting it to the REMS.         • Train all relevant staff involved in dispensing that the drug must be disper for administration by a healthcare provider, and that BRIXADI must not be         • Establish processes and procedures to verify BRIXADI is dispensed direct BRIXADI is not dispensed to a patient.         • Establish processes and procedures to notify the healthcare provider not Notifications may be accomplished through a variety of mechanisms bas calls, an auxiliary label printed automatically and affixed to the dispensed electronic medical record are potential mechanisms to communicate the         • Not distribute, transfer, loan, or sell BRIXADI.         • Maintain records of all processes and procedures including compliance w         • Comply with audits by Braeburn or a third party acting on behalf of Braeb procedures are in place and being followed for the BRIXADI REMS.	5-9384 Office fax: 923-885-3728 unication: Fax Ernail I Phone ocess and oversee implementation and y signing this form, I agree to:
First name: Jane       Last name: Smith         Position/Title:       Physician         Telephone number:       923-885-0931       Alternate telephone number:         Email:       jane.smith@testing.org       Preferred method of communication processes         I am the Authorized Representative designated to carry out the certification processes       Preferred method of communication processes         I am the Authorized Representative designated to carry out the certification processes       Preferred method of communication processes         I am the Authorized Representative designated to carry out the certification processes       Preferred method of communication processes         I am the Authorized Representative designated to carry out the certification processes and procedures to carry out the certification processes and procedures to verify BRIXADI must be dispersed for administration by a healthcare provider, and that BRIXADI must not be         • Establish processes and procedures to verify BRIXADI is dispensed direct BRIXADI is not dispensed to a patient.         • Establish processes and procedures to notify the healthcare provider not Notifications may be accomplished through a variety of mechanisms bas calls, an auxiliary label printed automatically and affixed to the dispensed electronic medical record are potential mechanisms to communicate the         • Not distribute, transfer, loan, or sell BRIXADI.       • Maintain records of all processes and procedures including compliance w         • Comply with audits by Braeburn or a third party acting on behalf of Braet procedures are in place and be	5-9384 Office fax: 923-885-3728 unication: Fax Ernail I Phone ocess and oversee implementation and y signing this form, I agree to:
<ul> <li>Position/Title: Physician</li> <li>Telephone number: 923-885-0931</li></ul>	5-9384 Office fax: 923-885-3728 unication: Fax Ernail I Phone ocess and oversee implementation and y signing this form, I agree to:
<ul> <li>Telephone number: 923-885-0931Alternate telephone number: 923-885</li> <li>Email: jane.smith@testing.orgPreferred method of communication of the second presentative designated to carry out the certification proceeding with the REMS on behalf of my healthcare setting or pharmacy. By</li> <li>Certify in the BRIXADI REMS by completing the Healthcare Setting and I submitting it to the REMS.</li> <li>Train all relevant staff involved in dispensing that the drug must be disper for administration by a healthcare provider, and that BRIXADI must not be</li> <li>Establish processes and procedures to verify BRIXADI is dispensed direct BRIXADI is not dispensed to a patient.</li> <li>Establish processes and procedures to notify the healthcare provider not Notifications may be accomplished through a variety of mechanisms bas calls, an auxiliary label printed automatically and affixed to the dispensed electronic medical record are potential mechanisms to communicate the</li> <li>Not distribute, transfer, loan, or sell BRIXADI.</li> <li>Maintain records of all processes and procedures including compliance we procedures are in place and being followed for the BRIXADI REMS.</li> </ul>	unication: Fax Email Phone ocess and oversee implementation and y signing this form, I agree to:
<ul> <li>Email: jane.smith@testing.org</li> <li>Preferred method of communication of the presentative designated to carry out the certification procompliance with the REMS on behalf of my healthcare setting or pharmacy. By</li> <li>Certify in the BRIXADI REMS by completing the Healthcare Setting and I submitting it to the REMS.</li> <li>Train all relevant staff involved in dispensing that the drug must be dispers for administration by a healthcare provider, and that BRIXADI must not be BRIXADI is not dispensed to a patient.</li> <li>Establish processes and procedures to verify BRIXADI is dispensed direct BRIXADI is not dispensed to a patient.</li> <li>Establish processes and procedures to notify the healthcare provider not Notifications may be accomplished through a variety of mechanisms bas calls, an auxiliary label printed automatically and affixed to the dispensed electronic medical record are potential mechanisms to communicate the Not distribute, transfer, loan, or sell BRIXADI.</li> <li>Maintain records of all processes and procedures including compliance were procedures are in place and being followed for the BRIXADI REMS.</li> </ul>	unication: Fax Email Phone ocess and oversee implementation and y signing this form, I agree to:
<ul> <li>I am the Authorized Representative designated to carry out the certification procompliance with the REMS on behalf of my healthcare setting or pharmacy. By</li> <li>Certify in the BRIXADI REMS by completing the Healthcare Setting and I submitting it to the REMS.</li> <li>Train all relevant staff involved in dispensing that the drug must be disper for administration by a healthcare provider, and that BRIXADI must not be</li> <li>Establish processes and procedures to verify BRIXADI is dispensed direct BRIXADI is not dispensed to a patient.</li> <li>Establish processes and procedures to notify the healthcare provider not Notifications may be accomplished through a variety of mechanisms bas calls, an auxiliary label printed automatically and affixed to the dispensed electronic medical record are potential mechanisms to communicate the</li> <li>Not distribute, transfer, loan, or sell BRIXADI.</li> <li>Maintain records of all processes and procedures including compliance w</li> <li>Comply with audits by Braeburn or a third party acting on behalf of Braet procedures are in place and being followed for the BRIXADI REMS.</li> </ul>	ocess and oversee implementation and y signing this form, I agree to:
<ul> <li>Maintain records of all processes and procedures including compliance v</li> <li>Comply with audits by Braeburn or a third party acting on behalf of Braeb procedures are in place and being followed for the BRIXADI REMS.</li> </ul>	ot to dispense directly to patients. sed on the healthcare setting. Phone d prescription, or reminders in the
<ul> <li>Comply with audits by Braeburn or a third party acting on behalf of Braeb procedures are in place and being followed for the BRIXADI REMS.</li> </ul>	
procedures are in place and being followed for the BRIXADI REMS.	with those processes and procedures.
By checking this box, you understand that your healthcare setting/pharmacy	burn to ensure that all processes and
Healthcare Setting or Pharmacy Authorized Representative Signature*:	Jane Smith.
Date* (MM/DD/YYYY):03 /31 /2023	
By signing I acknowledge that I understand that there is a risk of serious I intravenous self-administration of BRIXADI, and to not dispense BRIXADI that this enrollment applies to my bealthcare setting(s) or pharmacy(ies) is the set of the s	
	harm or death that could result from
	I directly to a patient. I understand

BRIXADI	REMS
---------	------

6 braeburn



## HEALTHCARE SETTING AND PHARMACY ENROLLMENT FORM (cont'd)

#### Healthcare Setting and Pharmacy Information

Street Address: 111 Healthy Way	City: Chicago	State: Illinois	sZIP:91919
Facility Identifiers (provide at least 1) NF	1:NCPDP:	DE	A: DD1232343
Authorized Representative Name: Jane	G Smith		
Primary Point of Contact IF NOT the Aut	horized Representative:		
Point of Contact Name: John Smith			
Street Address: 123 Healthy Road	City: Naperville	State: Illinois	ZIP: 91919
Telephone Number: 234-123-2345	Alternate Telephone Number: 3	45-234-3454 0	Office Fax: 456-435-456
Email: john.smith@testing.org	Preferred Method of Cor	mmunication: 🔲 Fax	🗹 Email 🔲 Phone
Setting Type			
Pharmacy			
Specialty Other:			

#### Healthcare Setting

Closed Healthcare System Criminal Justice Facility Criminal Justice Facility Pharmacy	
Department of Defense (DoD) Facility Federally Qualified Health Center (FOHC) FQHC Pharmacy	
Group Practice Hospital Hospital Pharmacy Independent Practice Institution	
🗆 Institution Pharmacy 🗹 Integrated Delivery Network (IDN) 📄 IDN Pharmacy 📄 Opioid Treatment Program (OT	P)
Outpatient Clinic Ueterans Administration (VA) Facility VA Pharmacy	
Other:	

3 of 3

**Close preview** 

## Submitter Notification Verbiage:

Update of REMS Notification:

Data pulled in from system or form data.

Subject:

"REMS ID XXXXXXXX has been updated"

Body:

"Healthcare Setting Doe Treatment Center is now re-enrolled in the BRIXADI REMS Program with the REMS ID XXXXXXXX. The Authorized Representative for XXXXXXXX is John Doe. <u>Click Here</u> to download or print your signed document.

For BRIXADI REMS Program questions 1-866-492-9624.

An additional site request has been sent to john.doe@test.com"

## New Enrollment Notfication:

Subject:

"REMS ID XXXXXXXX has been completed"

Body:

"Healthcare Setting Doe Treatment Center is now enrolled in the BRIXADI REMS Program with the REMS ID XXXXXXXX. The Authorized Representative for XXXXXXXX is John Doe. <u>Click Here</u> to download or print your signed document.

For BRIXADI REMS Program questions please contact 1-866-492-9624.

An additional site request has been sent to john.doe@test.com"

## Duplicate Enrollment Notification:

Subject:

"REMS ID XXXXXXXX has been updated"

Body:

"An Existing REMS Enrollment with REMS ID XXXXXXXX was identified. Due to the BRIXADI REMS reconciliation process your form has been updated. The REMS ID YYYYYYY is no longer valid. Please review the updated form XXXXXXXX.

For BRIXADI REMS Program questions please contact 1-866-492-9624."

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

CELIA J WINCHELL 05/23/2023 01:07:32 PM